Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice

van Rhijn, Bas W G; Catto, James W; Goebell, Peter J; Knüchel, Ruth; Shariat, Shahrokh F; van der Poel, Henk G; Sanchez-Carbayo, Marta; Thalmann, George; Schmitz-Dräger, Bernd J; Kiemeney, Lambertus A (2014). Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. Urologic oncology - seminars and original investigations, 32(7), pp. 1078-1087. Elsevier 10.1016/j.urolonc.2014.07.002

[img] Text
Thalmann_Urol Oncol_32_1078_Molecular markers.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (863kB) | Request a copy

OBJECTIVES To summarize the current status of clinicopathological and molecular markers for the prediction of recurrence or progression or both in non-muscle-invasive and survival in muscle-invasive urothelial bladder cancer, to address the reproducibility of pathology and molecular markers, and to provide directions toward implementation of molecular markers in future clinical decision making. METHODS AND MATERIALS Immunohistochemistry, gene signatures, and FGFR3-based molecular grading were used as molecular examples focussing on prognostics and issues related to robustness of pathological and molecular assays. RESULTS The role of molecular markers to predict recurrence is limited, as clinical variables are currently more important. The prediction of progression and survival using molecular markers holds considerable promise. Despite a plethora of prognostic (clinical and molecular) marker studies, reproducibility of pathology and molecular assays has been understudied, and lack of reproducibility is probably the main reason that individual prediction of disease outcome is currently not reliable. CONCLUSIONS Molecular markers are promising to predict progression and survival, but not recurrence. However, none of these are used in the daily clinical routine because of reproducibility issues. Future studies should focus on reproducibility of marker assessment and consistency of study results by incorporating scoring systems to reduce heterogeneity of reporting. This may ultimately lead to incorporation of molecular markers in clinical practice.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Thalmann, George

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1078-1439

Publisher:

Elsevier

Language:

English

Submitter:

Katharina Morgenegg

Date Deposited:

26 Feb 2015 14:36

Last Modified:

05 Nov 2015 10:37

Publisher DOI:

10.1016/j.urolonc.2014.07.002

PubMed ID:

25217465

Uncontrolled Keywords:

Urothelial, Bladder, Cancer, Molecular, Marker, Reproducibility

BORIS DOI:

10.7892/boris.63417

URI:

https://boris.unibe.ch/id/eprint/63417

Actions (login required)

Edit item Edit item
Provide Feedback